scholarly journals Tobacco mosaic virus for the targeted delivery of drugs to cells expressing prostate-specific membrane antigen

RSC Advances ◽  
2021 ◽  
Vol 11 (33) ◽  
pp. 20101-20108
Author(s):  
Sourabh Shukla ◽  
Isaac Marks ◽  
Derek Church ◽  
Soo-Khim Chan ◽  
Jonathan K. Pokorski ◽  
...  
Keyword(s):  
Tobacco Mosaic Virus ◽  
Mosaic Virus ◽  
Targeted Delivery ◽  
Prostate Gland ◽  
Prostate Specific Membrane Antigen ◽  
Important Target ◽  
Membrane Bound ◽  
Prostate Cancers ◽  
Specific Membrane

Prostate-specific membrane antigen (PSMA) is a membrane-bound protein that is preferentially expressed in the prostate gland and induced in many prostate cancers, making it an important target for new diagnostics and therapeutics.

Ultrastructure of tobacco mosaic virus lesions and surrounding tissue in Phaseolus vulgaris var. Pinto

1971 ◽  
Vol 49 (3) ◽  
pp. 417-421 ◽  
Author(s):  
D. F. Spencer ◽  
W. C. Kimmins
Keyword(s):  
Cell Wall ◽  
Electron Microscope ◽  
Phaseolus Vulgaris ◽  
Tobacco Mosaic Virus ◽  
Mosaic Virus ◽  
Healthy Tissue ◽  
Surrounding Tissue ◽  
Infected Area ◽  
Membrane Bound

Leaves of Phaseolus vulgaris var. Pinto were inoculated with the U1 strain of tobacco mosaic virus TMV (U1) and fully expanded lesions and adjacent healthy tissue were examined in the electron microscope. Emphasis was placed on the band of healthy cells (resistant zone) surrounding the lesion, with the object of detecting the first changes in ultrastructure as healthy tissue graded into the infected area. Cells in the resistant zone were characterized by the appearance of membrane-bound vesicular bodies (paramural bodies) between the plasmalemma and cell wall. Where paramural bodies accumulated, the plasmalemma was withdrawn and intercellular cytoplasmic connections through the plasmodesmata were severed. These changes were found most frequently for a distance of about three cell diameters beyond cells visibly infected at the lesion periphery. It is suggested that these changes in ultrastructure are related to the events of localization. Spread of the virus may be inhibited because of a lack of cytoplasmic connections between cells surrounding the virus-induced lesion.

Expression of prostate specific membrane antigen in the neo-vasculature of non-prostate cancers

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 3110-3110
Author(s):  
J. S. Ross ◽  
D. Schenkein ◽  
I. Webb ◽  
G. Gray ◽  
J. Deeds ◽  
...  
Keyword(s):  
Prostate Specific Membrane Antigen ◽  
Prostate Cancers ◽  
Specific Membrane

Expression of prostate specific membrane antigen in the neo-vasculature of non-prostate cancers

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 3110-3110 ◽  
Author(s):  
J. S. Ross ◽  
D. Schenkein ◽  
I. Webb ◽  
G. Gray ◽  
J. Deeds ◽  
...  
Keyword(s):  
Prostate Specific Membrane Antigen ◽  
Prostate Cancers ◽  
Specific Membrane

scholarly journals Surface Modification of Liposomes by a Lipopolymer Targeting Prostate Specific Membrane Antigen for Theranostic Delivery in Prostate Cancer

Materials ◽  
2019 ◽  
Vol 12 (5) ◽  
pp. 756 ◽  
Author(s):  
Hooman Yari ◽  
Gregory Nkepang ◽  
Vibhudutta Awasthi
Keyword(s):  
Prostate Cancer ◽  
Surface Modification ◽  
Surface Functionalization ◽  
Targeted Delivery ◽  
Prostate Specific Membrane Antigen ◽  
Lncap Cells ◽  
Binding Motifs ◽  
Ic50 Value ◽  
Pc3 Cells ◽  
Specific Membrane

Prostate specific membrane antigen (PSMA) is a marker for diagnosis and targeted delivery of therapeutics to advanced/metastasized prostate cancer. We report a liposome-based system for theranostic delivery to PSMA-expressing (PSMA+) LNCaP cells. A lipopolymer (P3) comprising of PSMA ligand (PSMAL), polyethylene glycol (PEG2000), and palmitate was synthesized and post-inserted into the surface of preformed liposomes. These P3-liposomes were loaded with doxorubicin and radiolabeled with 99mTc radionuclide to study their theranostic characteristics. Differential expression of PSMA on LNCaP and PC3 cells was confirmed by immunoblotting as well as by uptake of PSMAL labeled with 18F radionuclide. We found that the uptake of 99mTc-labeled P3-liposomes by LNCaP cells was >3-fold higher than 99mTc-labeled Plain-liposomes; the amount of doxorubicin delivered to LNCaP cells was also found to be >3-fold higher by P3-liposomes. Cell-based cytotoxicity assay results showed that doxorubicin-loaded P3-liposomes were significantly more toxic to LNCaP cells (p < 0.05), but not to PSMA-negative PC3 cells. Compared to doxorubicin-loaded Plain-liposomes, the IC50 value of doxorubicin-loaded P3-liposomes was reduced by ~5-fold in LNCaP cells. Together, these results suggest that surface functionalization of liposomes with small PSMA-binding motifs, such as PSMAL, can provide a viable platform for specific delivery of theranostics to PSMA+ prostate cancer.

scholarly journals Polypeptide-Based Molecular Platform and Its Docetaxel/Sulfo-Cy5-Containing Conjugate for Targeted Delivery to Prostate Specific Membrane Antigen

Molecules ◽  
2020 ◽  
Vol 25 (24) ◽  
pp. 5784
Author(s):  
Stanislav A. Petrov ◽  
Aleksei E. Machulkin ◽  
Anastasia A. Uspenskaya ◽  
Nikolay Y. Zyk ◽  
Ekaterina A. Nimenko ◽  
...  
Keyword(s):  
Targeted Delivery ◽  
Stereoselective Synthesis ◽  
Solid Phase ◽  
Fluorescent Label ◽  
Cytostatic Drug ◽  
Prostate Specific Membrane Antigen ◽  
Optimal Method ◽  
Carboxylic Groups ◽  
Theranostic Agents ◽  
Specific Membrane

A strategy for stereoselective synthesis of molecular platform for targeted delivery of bimodal therapeutic or theranostic agents to the prostate-specific membrane antigen (PSMA) receptor was developed. The proposed platform contains a urea-based, PSMA-targeting Glu-Urea-Lys (EuK) fragment as a vector moiety and tripeptide linker with terminal amide and azide groups for subsequent addition of two different therapeutic and diagnostic agents. The optimal method for this molecular platform synthesis includes (a) solid-phase assembly of the polypeptide linker, (b) coupling of this linker with the vector fragment, (c) attachment of 3-aminopropylazide, and (d) amide and carboxylic groups deprotection. A bimodal theranostic conjugate of the proposed platform with a cytostatic drug (docetaxel) and a fluorescent label (Sulfo-Cy5) was synthesized to demonstrate its possible sequential conjugation with different functional molecules.

scholarly journals Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer

2021 ◽  
Vol 22 (22) ◽  
pp. 12095
Author(s):  
Kristin A. Plichta ◽  
Stephen A. Graves ◽  
John M. Buatti
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Membrane Antigen ◽  
Resistant Disease ◽  
Stage Disease ◽  
Oligometastatic Prostate Cancer ◽  
Hormone Sensitive ◽  
Prostate Cancers ◽  
Castrate Resistant ◽  
Specific Membrane ◽  
Potential Use

Theranostics, a combination of therapy and diagnostics, is a field of personalized medicine involving the use of the same or similar radiopharmaceutical agents for the diagnosis and treatment of patients. Prostate-specific membrane antigen (PSMA) is a promising theranostic target for the treatment of prostate cancers. Diagnostic PSMA radiopharmaceuticals are currently used for staging and diagnosis of prostate cancers, and imaging can predict response to therapeutic PSMA radiopharmaceuticals. While mainly used in the setting of metastatic, castrate-resistant disease, clinical trials are investigating the use of PSMA-based therapy at earlier stages, including in hormone-sensitive or hormone-naïve prostate cancers, and in oligometastatic prostate cancers. This review explores the use of PSMA as a theranostic target and investigates the potential use of PSMA in earlier stage disease, including hormone-sensitive metastatic prostate cancer, and oligometastatic prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document